For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.
He first came into contact with the stock market and shares during his banking apprenticeship. After completing this in 2000, he gained his first journalistic experience in the editorial department of a financial portal. During his subsequent studies in business administration, he also worked in the area of investor relations.
Since then, he has remained true to the capital markets and is excited to report on every newly discovered interesting story - as well as on long-standing success stories.
Commented by Fabian Lorenz
Commented by Fabian Lorenz on May 5th, 2025 | 07:00 CEST
NEW PRICE TARGET: RENK, Novo Nordisk, and takeover candidate BioNxt Solutions
Analysts are raising their price target for RENK shares significantly. However, they appear to be trailing the current share price. Things will likely get exciting at RENK on May 15, when fresh figures and, hopefully, a well-filled order book will be reported. BioNxt Solutions shares are currently of interest. Clinical trials are about to begin on the development of the leading product for the easier treatment of multiple sclerosis. The stock is cheap and seen as a hot takeover candidate - perhaps for Novo Nordisk? With simplified administration, the Danes could further accelerate sales of Ozempic and potentially reduce costs. The stock is working on a bottom, and analysts recommend it as a "Buy".
Read
Commented by Fabian Lorenz on May 1st, 2025 | 07:10 CEST
A bombshell at Nel ASA! Buying opportunity for Bayer and Defence Therapeutics shares?
A bombshell at Nel ASA. The hydrogen specialist has reported its first quarter results: revenue and order intake are down, while the Company is sliding deep into the red. Will new major shareholder Samsung bring about a turnaround? Defence Therapeutics is a hot rebound candidate with takeover speculation. The biotech company is consistently pushing ahead with the monetization of its technology and has found a strong partner. The decline in the share price in recent months offers opportunities. A lot of negative news is certainly already priced into Bayer's share price, but is that enough to buy the stock? Yes, according to analysts.
Read
Commented by Fabian Lorenz on April 30th, 2025 | 07:15 CEST
Buy BioNTech after the crash? Valneva with vaccine problems! Vidac Pharma shares show potential!
BioNTech shares crashed by around 10% on Friday. So far, they have not been able to recover. What caused the setback? Should investors seize the opportunity? Analysts believe the German biotech heavyweight is on track. The same applies to Vidac Pharma. The news flow is extremely positive, but the stock is not making any headway. Analysts believe that Vidac shares could multiply in value. If the biotech company continues to be successful, a takeover could follow. And what is going on at Valneva? The stock is on a rollercoaster ride. Could a vaccine become a problem?
Read
Commented by Fabian Lorenz on April 29th, 2025 | 07:05 CEST
Out of RENK and Co. and into Almonty shares? China's sharpest sword! Another 100% price gain with the tungsten high-flyer?
"Restrictions on the export of rare earths are the sharpest sword China can wield," Harald Elsner of the German Raw Materials Agency told FAZ. Reserves are likely to last only a few weeks for German industry. While RENK, KNDS, and Co. are trembling in the face of export restrictions, Almonty's strategic importance for the Western defense industry and beyond is becoming increasingly clear. Like defense stocks, the tungsten producer's share price has more than doubled in the current year. However, the valuation remains low, and analysts see more than 100% upside potential. There are good reasons why the tungsten stock rocket could ignite the next stage as early as tomorrow.
Read
Commented by Fabian Lorenz on April 28th, 2025 | 07:00 CEST
Over 300% upside potential for cleantech stocks: Will dynaCERT finally outshine Nel, Plug Power, and Co.?
Analysts believe that dynaCERT shares are currently undervalued by more than 300%. The Company is on the verge of a breakthrough with its technology for reducing fuel consumption and emissions in diesel engines. Revenue is expected to multiply in the current year, with the trend continuing to rise sharply. Industry sentiment for cleantech and renewable energy stocks has also improved noticeably in recent weeks. This is because it is not only in Germany that the price of CO₂ is becoming a key lever for climate protection. dynaCERT helps companies save CO₂ and generate revenue through the sale of certificates. Perhaps Rheinmetall, KNDS, and Co. will follow suit in the future?
Read
Commented by Fabian Lorenz on April 25th, 2025 | 07:00 CEST
RENK BEFORE TAKEOVER? Will Evotec and AI gem NetraMark be swallowed up?
Is RENK on the verge of a takeover? In any case, the antitrust authorities have approved the entry of a new major shareholder. Could the takeover of the gearbox manufacturer herald a consolidation in the European defense industry, as announced by the head of Hensoldt? So far, there have only been small acquisitions, such as those of Rheinmetall. There is also movement in the pharmaceutical and biotech sectors. The Trump tariffs are shaking up the industry. NetraMark's AI software helps reduce costs and save time in drug research. The AI insider tip's stock still appears cheap and could skyrocket amid takeover speculation. Evotec has also been repeatedly mentioned as a takeover candidate. Yesterday, a large milestone payment was reported. How are the shares performing?
Read
Commented by Fabian Lorenz on April 24th, 2025 | 07:20 CEST
PRICE TARGET RISING! D-Wave, Palantir, Siemens Energy, and First Hydrogen
Companies such as D-Wave and Palantir are driving power consumption to ever-new heights with the future-oriented topics of quantum computing and artificial intelligence. Small modular reactors (SMRs) in combination with hydrogen are expected to provide a remedy. First Hydrogen recognized this megatrend early on and is pushing ahead with the integration of SMRs into its own hydrogen ecosystem. Following the recent sell-off, the stock offers an interesting entry opportunity. D-Wave itself recently reported a success in its cooperation with Japan Tobacco. This has nothing to do with tobacco but rather with accelerating drug development – another example of the use of quantum computing. Siemens Energy is also benefiting from rising energy consumption. After convincing quarterly figures, the share is at an all-time high. Analysts are raising their price targets.
Read
Commented by Fabian Lorenz on April 23rd, 2025 | 07:20 CEST
40% SHARE PRICE EXPLOSION! Commodity war drives Standard Lithium and BMW partner European Lithium! News from Evotec!
Price explosion at Standard Lithium! The share price rose by more than 40% yesterday. The joint venture with Norwegian energy company Equinor has been classified as a "critical mineral project" by the US government. This indicates that the raw materials war with China goes far beyond rare earths. European Lithium has lithium and rare earths to offer. The stock is a real bargain, as illustrated by the new details on the rare earth project in Greenland. Talks are already underway with defense companies from the US and Europe, and analysts see multiplication potential. Evotec shareholders had likely hoped for a somewhat bigger price explosion following the presentation of the new corporate strategy. However, the biotech company is bidding farewell to its strong growth trajectory.
Read
Commented by Fabian Lorenz on April 22nd, 2025 | 07:00 CEST
Gold price soon to reach USD 4,000! Profit with gold gem Tocvan Ventures! Share about to be taken over?
Will the tariff hammer be followed by a currency war? Speculation about the devaluation of the US dollar is already rife on the capital markets. One sign of this is that central banks are continuing to buy gold on a massive scale. After the price per troy ounce easily surpassed USD 3,300 last week, analysts are now targeting the USD 4,000 mark. The current environment makes it clear that gold belongs in every diversified portfolio. Tocvan Ventures is an exciting opportunity to jump on the gold bandwagon. The project in Mexico is at an advanced stage and is set to be developed into a world-class operation. After more than four years of exploration work, the project is expected to be given the green light in 2025. The share price has finally taken off, still has a lot of upside potential, should receive mining approval this year and offers takeover speculation.
Read
Commented by Fabian Lorenz on April 17th, 2025 | 08:15 CEST
Billions for defense and hydrogen: RENK, Nel ASA, and dynaCERT – Profiteer or "dead cat"?
In the coming years, billions will be invested in defense, hydrogen, and energy efficiency in Germany alone. The grand coalition has committed itself to this in the coalition agreement. The CO2 price is set to play a central role in climate protection. dynaCERT is expected to benefit from this, as the cleantech company's retrofit kits for diesel engines reduce CO₂ emissions. Analysts see multiple potential for the share. How quickly such a multiplication can happen has been recently demonstrated by RENK's share price. Despite hitting record highs, analysts recommend buying. And what is behind the price jump at Nel ASA? New hope, or are the Norwegians just a "dead cat bounce"?
Read